Unicycive Stock Climbs as FDA Takes Resubmitted Oxylanthanum Filing

what happened

Unicycive Therapeutics shares rose about 5% to $4 in morning trading, according to Dow Jones Newswires, though the stock is still down 19% over the past year. The move followed the company's announcement that the US Food and Drug Administration has taken its resubmitted new drug application for oxylanthanum carbonate under review.

The drug is an investigational oral phosphate binder aimed at hyperphosphatemia in chronic kidney disease patients on dialysis. Unicycive refiled after receiving a Complete Response Letter in June. The FDA classified the resubmission as Class II, giving it a six-month review from the resubmission date, with a PDUFA target action date of March 25, 2027.

The company said it is uncertain whether the agency will require a pre-approval check of the newly named outside supplier for the finished product. If the original third-party manufacturer is inspected soon and found compliant with good manufacturing practice, Unicycive plans to seek agreement on a shorter approval timeline. The timing and result of any inspection rest entirely with the FDA.

why it matters

For the broader market this is a small-cap biotech update with limited spillover. For investors it highlights regulatory timing risk, since approval hinges on inspections at third-party manufacturers that the company does not control. The FDA decision expected in March 2027 will shape the stock's next move.

tags

instruments